Sarepta Therapeutics has activated a $100 million milestone payment to Arrowhead Pharmaceuticals following positive safety data in its SRP-1003 myotonic dystrophy program. To finance this, Sarepta sold over nine million Arrowhead shares and transferred additional equity. Concurrently, Sarepta announced a strategic overhaul including a 36% workforce reduction to focus resources on its most promising programs and meet 2027 financial targets. This restructuring reflects efforts to maintain financial sustainability while advancing RNAi-based and other precision genetics therapies.